Biosimilar Newsletter Archive

21. 01.10.19 -- Top 5 Biosimilar Developments Of 2018
    1/10/2019
    01/10/19 Biosimilar Development Newsletter
22. 01.03.19 -- What Biosimilar Metamorphases Are In Store For 2019?
    1/3/2019
    01/03/19 Biosimilar Development Newsletter
23. 12.20.18 -- How Did 2018 Impact Biosimilar Market Expectations?
    12/20/2018
    12/20/18 Biosimilar Development Newsletter
24. 12.18.18 -- Biosimilar Development Top 10 Of 2018
    12/18/2018
    12/18/18 Biosimilar Development Newsletter
25. 12.15.18 -- Embracing Uncertainty By Bringing Optionality Into Facility And Capacity Planning
    12/15/2018
    12/15/18 Biosimilar Development Newsletter
26. 12.13.18 -- How Will Trump's FTC/DOJ Reporting Requirement Impact Biosimilars?
    12/13/2018
    12/13/18 Biosimilar Development Newsletter
27. 12.08.18 -- Biosimilars Vs. AbbVie: Humirapocalypse Or Growing Pains?
    12/8/2018
    12/08/18 Biosimilar Development Newsletter
28. 12.06.18 -- U.S. Biosimilar Progress: How Should We Really Feel?
    12/6/2018
    12/06/18 Biosimilar Development Newsletter
29. 12.04.18 -- Considerations In API Scale Up Strategy
    12/4/2018
    12/04/18 Biosimilar Development Newsletter
30. 11.29.18 -- Mylan's Pegfilgrastim: Retracing Its Fulphila Journey
    11/29/2018
    11/29/18 Biosimilar Development Newsletter